Abstract: Treatment of gynaecological cancer frequently results in the loss of ovarian function and menopausal syndrome. The most effective treatment is hormone replacement therapy (HRT). According to the current studies, HRT does not increase the risk of recurrence or death in patients with early stage endometrial cancer and uterine leiomyosarcomas. The safety of HRT in ovarian cancer patients is inconclusive. Cervical squamous cell carcinoma, vaginal cancer and vulvar cancer are not contraindications for HRT. Estrogen replacement therapy（ERT） is contraindicated for lowgrade endometrial stromal sarcomas. Therefore, after integrated risk assessment and discussion, patients with severe menopausal symptoms can be treated with HRT to improve the quality of life. 

Key words: Hormone replacement therapy, Menopause, Genital neoplasms, female